High-dose cyclophosphamide (NSC-26271) for recurrent or progressive ovarian adenocarcinoma
Piver, M.S.; Barlow, J.J.; Chung, W.S.
Cancer ChemoTherapy Reports 59(6): 1157-1158
1975
ISSN/ISBN: 0069-0112 PMID: 769956 Document Number: 86824
Document emailed within 1 workday
Related Documents
Carter, J.L.; Hafler, D.A.; Dawson, D.M.; Orav, J.; Weiner, H.L. 1988: Immunosuppression with high-dose I.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients Neurology 38(7 Suppl 2: 9-14Wada, N.; Kobayashi, H.; Oka, S.; Ando, J.; Tamura, H. 2002: Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(11): 1935-1942
Sevelda, P.; Dittrich, C.; Salzer, H.; Pateisky, N.; Spona, J. 1986: Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125 Cancer Detection and Prevention 9(5-6): 521-528
Hancock, K.C.; Freedman, R.S.; Edwards, C.L.; Rutledge, F.N. 1986: Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium Cancer Treatment Reports 70(6): 789-791
Watanabe, T.; Yamamoto, T.; Saito, T.; Sugano, M.; Tsukamoto, T. 1993: Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis Rinsho Shinkeigaku 33(1): 15-20
Lovecchio, J.L.; Averette, H.E.; Lichtinger, M.; Townsend, P.A.; Girtanner, R.W.; Fenton, A.N. 1984: Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate Obstetrics and Gynecology 63(4): 557-560
Iwasaki, K.; Komuro, Y.; Masumoto, N.; Asaoka, K.; Ishitani, K. 1999: A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(10): 1483-1486
Santini, G.; Coser, P.; Congiu, A.M.; Salvagno, L.; De Souza, C.; Sertoli, M.R.; Olivieri, A.; Chisesi, T.; Rubagotti, A.; Truini, M.; Contu, A.; Porcellini, A.; Zambaldi, G.; Nati, S.; Marino, G.; Rizzoli, V. 2000: VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group Haematologica 85(2): 160-166
Charak, B.S. 1991: Amelioration of high dose cyclophosphamide-induced myelosuppression National Medical Journal of India 4(1): 30
Fennelly, D.W.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; O'Connor, K.; Curtin, J.P.; Crown, J.P.; Hoskins, W.J.; Spriggs, D.R. 1997: Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer Seminars in Oncology 24(1 Suppl 2: S2
Fasola, G.; Lo Greco, P.; Calori, E.; Zilli, M.; Verlicchi, F.; Motta, M.R.; Ricci, P.; Baccarani, M.; Tura, S. 1991: Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation Haematologica 76(2): 120-125
Mittal, G.; Balakrishnan, C.; Mangat, G.; Joshi, V.R. 1999: High dose cyclophosphamide in the treatment of systemic lupus erythematosus Journal of the Association of Physicians of India 47(7): 747
Shepp, M.; Necheles, T.F.; Banks, H.H.; Oh, W.H.; Zimbler, S. 1978: Adjuvant treatment of osteogenic sarcoma with high-dose cyclophosphamide Cancer Treatment Reports 62(2): 295-296
van Heusden, A.M.; Coelingh Bennink, H.J.T.; Fauser, B.C.J.M. 2002: FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives Clinical Endocrinology 56(4): 509-517
Tremann, J.A.; Haines, J.G.; Bleifuss, J.H.; Agodoa, L.C.; Marchioro, T.L. 1975: The effect of high dose steroid and cyclophosphamide on perfused canine renal homografts Transplantation 19(6): 520-522
Ettinger, D.S.; Karp, J.E.; Abeloff, M.D.; Burke, P.J.; Braine, H.G. 1978: Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung Cancer Treatment Reports 62(3): 413-424
Wetzel, V.; Schaumlöffel, E.; Jankowski, R.P. 1978: In vitro sensitivity testing of cells of histologically typified ovarian carcinomas and carcinoma of corpus with 3H-cyclophosphamide-metabolites in the serum of man after massive dose therapy International Journal of Clinical Pharmacology and Biopharmacy 16(12): 600-606
Uysal, M.; Ozdogan, M.; Kargi, A.; Gunduz, S.; Sezgin Goksu, S.; Murat Tatli, A.; Arslan, D.; Mutlu, H.; Senol Coskun, H.; Bozcuk, H. 2014: Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 19(4): 980-984
Gardner, S.F.; Lazarus, H.M.; Bednarczyk, E.M.; Creger, R.J.; Miraldi, F.D.; Leisure, G.; Green, J.A. 1993: High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography Bone Marrow Transplantation 12(2): 139-144
Trouillas, P.; Neuschwander, P.; Nighoghossian, N.; Adeleine, P.; Tremisi, P. 1989: Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years Revue Neurologique (Paris) 145(5): 369-377